4.22
Lexeo Therapeutics Inc stock is traded at $4.22, with a volume of 663.29K.
It is up +4.98% in the last 24 hours and up +55.15% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
See More
Previous Close:
$4.02
Open:
$4.03
24h Volume:
663.29K
Relative Volume:
0.67
Market Cap:
$153.01M
Revenue:
-
Net Income/Loss:
$-86.60M
P/E Ratio:
-1.4899
EPS:
-2.8324
Net Cash Flow:
$-67.37M
1W Performance:
+0.24%
1M Performance:
+55.15%
6M Performance:
-35.87%
1Y Performance:
-72.97%
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
LXEO
Lexeo Therapeutics Inc
|
4.22 | 153.01M | 0 | -86.60M | -67.37M | -2.8324 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-13-24 | Initiated | Robert W. Baird | Outperform |
Jun-06-24 | Initiated | H.C. Wainwright | Buy |
Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
Nov-28-23 | Initiated | JP Morgan | Overweight |
Nov-28-23 | Initiated | Leerink Partners | Outperform |
Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Bank of America Corp DE Trims Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics files to sell 41.63M shares of common stock for holders - MSN
Lexeo Therapeutics (LXEO) Proposes Sale of 41.63 Million Shares - GuruFocus
Lexeo Therapeutics Registers Share Offering on Behalf of Selling Stockholders - MarketScreener
Lexeo Therapeutics (LXEO) Proposes Sale of 41.63 Million Shares | LXEO Stock News - GuruFocus
Jane Street Group LLC Reduces Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stake Lifted by Wellington Management Group LLP - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Acquired by Millennium Management LLC - Defense World
Deutsche Bank AG Buys 8,378 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Wilson Sonsini Advises Lexeo Therapeutics on $80 Million Private Placement Equity Financing - Wilson Sonsini
Lexeo Therapeutics (NASDAQ:LXEO) Given New $10.00 Price Target at JPMorgan Chase & Co. - Defense World
Leerink Partnrs Issues Optimistic Outlook for LXEO Earnings - Defense World
Lexeo Therapeutics (LXEO) Price Target Lowered by JP Morgan | LX - GuruFocus
Lexeo Therapeutics (LXEO) Price Target Lowered by JP Morgan | LXEO Stock News - GuruFocus
BNP Paribas Financial Markets Buys 28,986 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Northern Trust Corp Acquires 14,185 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo raises $80 million to shore up gene therapy work after layoffs - The Pharma Letter
Leerink cuts Lexeo Therapeutics price target to $10, maintains outlook - Investing.com Australia
Leerink cuts Lexeo Therapeutics price target to $10, maintains outlook By Investing.com - Investing.com India
Lexeo Therapeutics raises $80M in private placement (LXEO) - Seeking Alpha
Lexeo Therapeutics secures $80 million in private placement By Investing.com - Investing.com South Africa
Lexeo Therapeutics (LXEO) Secures $80M from Private Placement | - GuruFocus
Lexeo Therapeutics Announces $80 Mln Private Placement Of Shares - Nasdaq
Lexeo Therapeutics Announces $80 Million Equity Financing - marketscreener.com
Lexeo prices 20.8M shares at $2.8825 in private placement - TipRanks
Lexeo Therapeutics Announces $80M Private Placement Agreement - TipRanks
Lexeo Therapeutics (LXEO) Secures $80M from Private Placement | LXEO Stock News - GuruFocus
Lexeo Therapeutics secures $80 million in private placement - Investing.com
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases - The Manila Times
Lexeo Therapeutics Secures $80 Million Financing to Extend Cash Runway into 2028 for Clinical Programs - Nasdaq
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of ... - Bluefield Daily Telegraph
Major Investors Back Lexeo Therapeutics with $80M for Breakthrough Genetic Heart Disease Programs - Stock Titan
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of “Buy” by Brokerages - Defense World
Price T Rowe Associates Inc. MD Acquires New Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Q1 Earnings Forecast for LXEO Issued By HC Wainwright - Defense World
FY2025 Earnings Forecast for LXEO Issued By Chardan Capital - Defense World
HC Wainwright Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $15.00 - Defense World
Lexeo stock price target cut to $15 by H.C. Wainwright - Investing.com South Africa
Lexeo Therapeutics price target lowered to $15 from $23 at H.C. Wainwright - TipRanks
Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Superior Safety Profile Drive Buy Rating - TipRanks
#ASGCT25: In three patients, Rocket’s second heart gene therapy shows promise - Endpoints News
Lexeo Therapeutics (LXEO) Analyst Rating Update and Price Target Adjustment | LXEO Stock News - GuruFocus
Lexeo Therapeutics (LXEO) Price Target Cut to $15 by H.C. Wainwr - GuruFocus
Leerink Partnrs Has Bearish Forecast for LXEO Q2 Earnings - Defense World
Chardan Capital Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price - Defense World
Lexeo Therapeutics: Strategic Focus and Promising Pipeline Drive Buy Rating - TipRanks
Lexeo Therapeutics (LXEO) Sees Price Target Adjustment by Charda - GuruFocus
Chardan Adjusts Price Target on Lexeo Therapeutics to $20 From $22, Maintains Buy Rating - marketscreener.com
Lexeo Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
Lexeo Therapeutics price target lowered to $20 from $22 at Chardan - TipRanks
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexeo Therapeutics Inc Stock (LXEO) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Adler Eric | Chief Medical Officer |
May 16 '25 |
Sale |
2.77 |
585 |
1,623 |
67,681 |
Robertson Jenny | Chief Legal Officer |
May 16 '25 |
Sale |
2.77 |
521 |
1,445 |
63,098 |
See Tai Sandi | Chief Development Officer |
May 16 '25 |
Sale |
2.77 |
367 |
1,018 |
59,242 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):